News | March 27, 2026
CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Doctors at the hospital highlighted that robotic-assisted surgery enhances precision through superior 3D visualisation and improved instrument flexibility
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
Subscribe To Our Newsletter & Stay Updated
